Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, ...

HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, ...

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial ...

Need a quote from a Motley Fool analyst? Total Revenue -- $24 million, a 30% increase, attributed chiefly to expansion in ...

Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...

So now, you know, we have competing standards of care in the frontline for AML, which is either high intensity induction or ...

I think probably the best one is the urban patient who has access to an academic medical center that is running clinical ...

Researchers sought to determine whether adding selinexor to chemotherapeutic induction and consolidation regimen would improve outcomes in AML.